AstraZeneca (AZN.US) has launched its monoclonal antibody new drug for two indications in China.

Zhixin Finance APP learned that on August 17, AstraZeneca (AZN.US) announced the official launch of Tezepelumab injection in China. Tezepelumab is a biological agent for the treatment of severe asthma, overcoming limitations of phenotype and biomarker levels, targeting thymic stromal lymphopoietin (TSLP).